Testing effectiveness (Phase 2)UnknownNCT06427005What this trial is testingFruquintinib Plus S-1 and Raltitrexed (RSF) for MCRCWho this might be right forFruquintinibS-1Raltitrexed Meng Qiu 66
Testing effectiveness (Phase 2)WithdrawnNCT05966233What this trial is testingR-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell LymphomaWho this might be right forDiffuse Large B Cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma Recurrent Fondazione Italiana Linfomi - ETS
Large-scale testing (Phase 3)Not Yet RecruitingNCT07786922What this trial is testingAvatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard TreatmentWho this might be right forAplastic Anemia Swedish Orphan Biovitrum 26
Early research (Phase 1)Study completedNCT00736372What this trial is testingA Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic CancerWho this might be right forMetastatic CancerAdvanced Cancer Cascadian Therapeutics Inc. 14
Not applicableUnknownNCT06009835What this trial is testingDOTr/DOTa Algorithm Guidance for Refractory Solid TumorsWho this might be right forSolid TumorIndividuation Tianjin Medical University Second Hospital 15
Testing effectiveness (Phase 2)Study completedNCT02870920What this trial is testingDurvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal CancerWho this might be right forColorectal Cancer Canadian Cancer Trials Group 180
Testing effectiveness (Phase 2)Ended earlyNCT00441168What this trial is testingVelcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple MyelomaWho this might be right forMultiple Myeloma Janssen-Cilag International NV 30
Testing effectiveness (Phase 2)Study completedNCT00054613What this trial is testingSafety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host DiseaseWho this might be right forGraft-versus-Host Disease Mallinckrodt 72
Large-scale testing (Phase 3)Study completedNCT02138422What this trial is testingEvaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal CancerWho this might be right forSymptomatic Colorectal CancerAdvanced Colorectal CancerColorectal Cancer With Cachexia Janssen Research & Development, LLC 276
Large-scale testing (Phase 3)Looking for participantsNCT06561048What this trial is testingSoquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaWho this might be right forPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell Lymphoma+4 more Corvus Pharmaceuticals, Inc. 150
Testing effectiveness (Phase 2)Looking for participantsNCT07602049What this trial is testingCryoablation Plus Camrelizumab for Advanced Soft Tissue SarcomaWho this might be right forSoft Tissue Sarcoma (STS)Osteosarcoma Sun Yat-sen University 57
Early research (Phase 1)Study completedNCT02675491What this trial is testingPhase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant TumorsWho this might be right forAdvanced Solid Malignant Tumors Daiichi Sankyo Co., Ltd. 15
Large-scale testing (Phase 3)Ended earlyNCT03221842What this trial is testingEfficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant RecipientsWho this might be right forAntibody-mediated Rejection CSL Behring 63
Early research (Phase 1)Study completedNCT02499224What this trial is testingSafety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard TherapyWho this might be right forSolid Tumors CellabMED 39
Testing effectiveness (Phase 2)Study completedNCT00004758What this trial is testingPhase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard TreatmentWho this might be right forSpasms, InfantileEpilepsy National Center for Research Resources (NCRR) 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05428969What this trial is testingAssess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesWho this might be right forAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes+1 more Faron Pharmaceuticals Ltd 181
Testing effectiveness (Phase 2)Study completedNCT00284817What this trial is testingPhase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal CancerWho this might be right forCancer MedImmune LLC 17
Early research (Phase 1)Looking for participantsNCT05272371What this trial is testingImmunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive DiseaseWho this might be right forHigh-Risk Neuroblastoma Jagiellonian University 20
Testing effectiveness (Phase 2)Looking for participantsNCT07559864What this trial is testingComparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentWho this might be right forGIST - Gastrointestinal Stromal TumorKIT Gene Mutation Jian Li 100
Large-scale testing (Phase 3)Study completedNCT00995709What this trial is testingPhase III Study in Refractory Behcet's DiseaseWho this might be right forBehcet Disease Novartis Pharmaceuticals 118